Lung Cancer News

Bevacizumab Plus Erlotinib May Be a New Standard of Care in Non-Small Cell Lung Cancer

Bevacizumab Plus Erlotinib May Be a New Standard of Care in Non-Small Cell Lung Cancer

Recent studies have explored the potential of combination therapy with EGFR-TKIs and VEGF-inhibitors for patients with EGFR-positive non-small cell lung cancer.

Gefitinib Plus Platinum-Doublet Chemotherapy May Improve Overall Survival in EGFR-Positive NSCLC

Gefitinib Plus Platinum-Doublet Chemotherapy May Improve Overall Survival in EGFR-Positive NSCLC

EGFR tyrosine kinase inhibitor monotherapy has improved progression-free survival (PFS) but not overall survival (OS) compared with chemotherapy in non-small cell lung cancer.

Web-Based Monitoring Resulted in Longer Overall Survival for Patients in Lung Cancer

Web-Based Monitoring Resulted in Longer Overall Survival for Patients in Lung Cancer

Previous findings showed a 7 month median overall survival benefit (P = .002) for patients with lung cancer given web-mediated follow-up.

Lung Cancer Screening Rates Inadequate in United States Despite USPSTF Recommendations

Lung Cancer Screening Rates Inadequate in United States Despite USPSTF Recommendations

Current literature reflects estimates, but not actual rates, of low-dose computed tomography adherence across the United States.

Prophylactic Cranial Irradiation Reduces the Incidence of Brain Metastases in NSCLC

Prophylactic Cranial Irradiation Reduces the Incidence of Brain Metastases in NSCLC

Some figures show that incidence of brain metastasis is approximately 30% 2 years after being diagnosed with non-small cell lung cancer.

Timely Reporting of Palliative Care Needs Leads to More Appropriate End-of-Life Care in NSCLC

Timely Reporting of Palliative Care Needs Leads to More Appropriate End-of-Life Care in NSCLC

Researchers accessed the French National Hospital registry and obtained the records of 64,950 patients who died of metastatic NSCLC between 2010 and 2013.

Osimertinib Improves Quality-of-Life and Global Health Status in Non-Small Cell Lung Cancer

Osimertinib Improves Quality-of-Life and Global Health Status in Non-Small Cell Lung Cancer

Non-small cell lung cancer largely remains incurable and is associated with high symptom burden and reduced quality of life.

Phase 1/2 Trial of CAR-T Cell Immunotherapy in Metastatic, Mesothelin-Expressing Cancer

Phase 1/2 Trial of CAR-T Cell Immunotherapy in Metastatic, Mesothelin-Expressing Cancer

Researchers are evaluating whether CAR-T cell immunotherapy that targets mesothelin is safe and effective among patients with mesothelin-expressing tumors.

CTCs May Not Have Genetic Changes Found in Primary Lung Tumors

CTCs May Not Have Genetic Changes Found in Primary Lung Tumors

At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.

Crizotinib Leads to Durable Benefit in ROS1-Positive Non-Small Cell Lung Cancer

Crizotinib Leads to Durable Benefit in ROS1-Positive Non-Small Cell Lung Cancer

Previous studies have demonstrated that crizotinib — a tyrosine kinase inhibitor (TKI) of ALK, MET, and ROS1 kinases — has markedly increased antitumor activity among patients with ROS1-positive NSCLC.

Long-Term Gefitinib Can Be Effective in Patients With NSCLC

Long-Term Gefitinib Can Be Effective in Patients With NSCLC

Few long-term data of the drug's safety and efficacy in patients with NSCLC were previously available.

Randomized Trial of Stepped vs Early Integrated Palliative Care for Lung Cancer

Randomized Trial of Stepped vs Early Integrated Palliative Care for Lung Cancer

Researchers are evaluating whether early integrated palliative care yields superior quality of life outcomes to stepped palliative care.

NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status

NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status

Cancer-associated weight loss is linked to worse survival outcomes among patients with cancer.

Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC

Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC

The safety profile of each agent was consistent with those previously reported.

NSCLC: Stratifying Patients With Complex EGFR Mutations

NSCLC: Stratifying Patients With Complex EGFR Mutations

Researchers evaluated whether different complex mutations lead to different clinical outcomes among patients treated with EGFR-TKIs.

NSCLC: Fruquintinib May Prolong PFS in Third-, Fourth-Line Setting

NSCLC: Fruquintinib May Prolong PFS in Third-, Fourth-Line Setting

Previous studies demonstrated that fruquintinib may have clinical value for patients who fail at least 2 prior lines of therapy.

Phase 2 Trial of AZD1775 for Squamous Cell Lung Cancer

Phase 2 Trial of AZD1775 for Squamous Cell Lung Cancer

AZD1775 is an inhibitor of the Wee1 kinase, which is linked to chemotherapy resistance.

Phase 2 Study of Tremelimumab Plus Durvalumab Alone or With Radiation for SCLC

Phase 2 Study of Tremelimumab Plus Durvalumab Alone or With Radiation for SCLC

Researchers are evaluating the efficacy of tremelimumab plus durvalumab alone or with radiation therapy among patients with SCLC.

Phase 2 Study of Pembrolizumab vs Topotecan for Small-Cell Lung Cancer

Phase 2 Study of Pembrolizumab vs Topotecan for Small-Cell Lung Cancer

Researchers are comparing the effectiveness of pembrolizumab with that of topotecan among patients with SCLC.

Cigar and Pipe Use Significantly Increase Mortality Risk

Cigar and Pipe Use Significantly Increase Mortality Risk

Non-cigarette tobacco use has increased by over 100% in the last 2 decades.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs